-
1.发明申请Use of a Cytokine From the Interleukin-6 Family In the Preparation of a Composition For Combined Administration With Interferon-Alpha 有权使用白细胞介素-6家族的细胞因子在制备与干扰素-α组合施用的组合物公开(公告)号：US20090130055A1
公开(公告)日：2009-05-21
申请号：US11922221
申请日：2006-06-16
申请人： Rafael Aldabe Arregui , Esther Larrea Leoz , Maria Pilar Civeira Murillo , Jesus Prieto Valtuena
发明人： Rafael Aldabe Arregui , Esther Larrea Leoz , Maria Pilar Civeira Murillo , Jesus Prieto Valtuena
IPC分类号： A61K38/20 , A61K31/7088
CPC分类号： C07K14/5412 , A61K38/00 , A61K38/19 , A61K38/212 , C07K14/5415 , C07K14/5431 , A61K2300/00
摘要： The invention relates to the use of at least one cytokine from the IL-6 family −gp130, preferably selected from among IL-11, the leukaemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1, ciliary neurotrophic factor (CNTF), the cardiotrophin-like cytokine (CLC) and combinations thereof or a DNA sequence encoding same, in the preparation of a pharmaceutical composition which is intended for combined administration with at least one IFN-α or a DNA sequence encoding same, for use in the treatment of viral diseases. The invention also relates to a pharmaceutical composition comprising a pharmaceutically-acceptable quantity of at least one cytokin from the IL-6 family −gp130 or a DNA sequence encoding same and a pharmaceutically-acceptable quantity of at least one IFN-α or a DNA sequence encoding same, a pharmaceutical kit and a method for the treatment of viral diseases with the combined administration of the aforementioned cytokines and IFN-α.
摘要翻译： 本发明涉及来自IL-6家族-gp130的至少一种细胞因子，优选选自IL-11，白血病抑制因子（LIF），制瘤素M（OSM），心肌营养因子-1，睫状神经营养因子 CNTF），心肌营养素样细胞因子（CLC）及其组合，或编码该DNA序列的DNA序列，用于制备药物组合物，其用于与至少一种IFN-α或编码该IFN-α或DNA序列的组合施用，以供使用 在治疗病毒性疾病。 本发明还涉及药物组合物，其包含药学上可接受量的至少一种来自IL-6家族-gp130的细胞素或编码其的DNA序列和药学上可接受量的至少一种IFN-α或DNA序列 编码它们，药物试剂盒和通过联合施用上述细胞因子和IFN-α来治疗病毒性疾病的方法。
-
2.发明授权Treatment of hepatitis C with compositions comprising oncostatin M and interferon alpha 有权用含有制瘤素M和干扰素α的组合物治疗丙型肝炎公开(公告)号：US07829077B2
公开(公告)日：2010-11-09
申请号：US11922221
申请日：2006-06-16
申请人： Rafael Aldabe Arregui , Esther Larrea Leoz , María Pilar Civeira Murillo , Jesús Prieto Valtueña
发明人： Rafael Aldabe Arregui , Esther Larrea Leoz , María Pilar Civeira Murillo , Jesús Prieto Valtueña
CPC分类号： C07K14/5412 , A61K38/00 , A61K38/19 , A61K38/212 , C07K14/5415 , C07K14/5431 , A61K2300/00
摘要： The invention relates to the use of at least one cytokine from the IL-6 family -gp130, preferably selected from among IL-11, the leukaemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1, ciliary neurotrophic factor (CNTF), the cardiotrophin-like cytokine (CLC) and combinations thereof or a DNA sequence encoding same, in the preparation of a pharmaceutical composition which is intended for combined administration with at least one IFN-α or a DNA sequence encoding same, for use in the treatment of viral diseases. The invention also relates to a pharmaceutical composition comprising a pharmaceutically-acceptable quantity of at least one cytokin from the IL-6 family −gp130 or a DNA sequence encoding same and a pharmaceutically-acceptable quantity of at least one IFN-α or a DNA sequence encoding same, a pharmaceutical kit and a method for the treatment of viral diseases with the combined administration of the aforementioned cytokines and IFN-α.
摘要翻译： 本发明涉及来自IL-6家族-gp130的至少一种细胞因子，优选选自IL-11，白血病抑制因子（LIF），制瘤素M（OSM），心肌营养因子-1，睫状神经营养因子 CNTF），心肌营养素样细胞因子（CLC）及其组合，或编码该DNA序列的DNA序列，用于制备药物组合物，其用于与至少一种IFN-α或其编码的DNA序列组合施用，以供使用 在治疗病毒性疾病。 本发明还涉及包含药学上可接受量的来自IL-6家族-gp130的至少一种细胞素的药物组合物或其编码的DNA序列和药学上可接受量的至少一种IFN-α或DNA序列 编码相同的药物试剂盒，以及通过联合给药上述细胞因子和IFN-α来治疗病毒性疾病的方法。
-
3.发明申请USE OF A CYTOKINE FROM THE INTERLEUKIN-6 FAMILY IN THE PREPARATION OF A COMPOSITION FOR COMBINED ADMINISTRATION WITH INTERFERON-ALPHA 审中-公开来自INTERLEUKIN-6家族的细胞因子在制备与干扰素ALPHA联合给药的组合物中的应用公开(公告)号：US20110027224A1
公开(公告)日：2011-02-03
申请号：US12887843
申请日：2010-09-22
申请人： Rafael Aldabe Arregui , Esther Larrea Leoz , María Pilar Civeira Murillo , Jesús Prieto Valtueña
发明人： Rafael Aldabe Arregui , Esther Larrea Leoz , María Pilar Civeira Murillo , Jesús Prieto Valtueña
CPC分类号： C07K14/5412 , A61K38/00 , A61K38/19 , A61K38/212 , C07K14/5415 , C07K14/5431 , A61K2300/00
摘要： The invention relates to the use of at least one cytokine from the IL-6 family −gp130, preferably selected from among IL-11, the leukaemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1, ciliary neurotrophic factor (CNTF), the cardiotrophin-like cytokine (CLC) and combinations thereof or a DNA sequence encoding same, in the preparation of a pharmaceutical composition which is intended for combined administration with at least one IFN-α or a DNA sequence encoding same, for use in the treatment of viral diseases. The invention also relates to a pharmaceutical composition comprising a pharmaceutically-acceptable quantity of at least one cytokin from the IL-6 family −gp130 or a DNA sequence encoding same and a pharmaceutically-acceptable quantity of at least one IFN-α or a DNA sequence encoding same, a pharmaceutical kit and a method for the treatment of viral diseases with the combined administration of the aforementioned cytokines and IFN-α.
摘要翻译： 本发明涉及来自IL-6家族-gp130的至少一种细胞因子，优选选自IL-11，白血病抑制因子（LIF），制瘤素M（OSM），心肌营养因子-1，睫状神经营养因子 CNTF），心肌营养素样细胞因子（CLC）及其组合，或编码该DNA序列的DNA序列，用于制备药物组合物，其用于与至少一种IFN-α或其编码的DNA序列组合施用，以供使用 在治疗病毒性疾病。 本发明还涉及包含药学上可接受量的来自IL-6家族-gp130的至少一种细胞素的药物组合物或其编码的DNA序列和药学上可接受量的至少一种IFN-α或DNA序列 编码相同的药物试剂盒，以及通过联合给药上述细胞因子和IFN-α来治疗病毒性疾病的方法。
-
公开(公告)号：US20060188477A1
公开(公告)日：2006-08-24
申请号：US11212126
申请日：2005-08-25
CPC分类号： A61K38/212 , Y10S514/893 , Y10S514/894
摘要： The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFNα5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the subtype alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFNα5. These significant differences between the expression patterns of some livers an others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatopathies. The invention discloses in details such utilization in different forms and processes, including those which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.
摘要翻译： 本发明涉及干扰素α5在病毒性肝病的治疗中的应用。 本发明描述了与健康肝脏相比，丙型肝炎患者肝脏中IFNα5的合成减少。 在所述健康肝脏中表达的IFN的亚型与仅在肝脏中表达的不同亚型相比仅对应于α5亚型。 序列SEQ ID NO：1显示对应于IFNα5的cDNA的部分序列。 一些肝脏的表达模式之间的这些显着差异表明了使用这种干扰素亚型在制备可用于治疗病毒性肝病的组合物中的重要性。 本发明详细公开了不同形式和方法的这种利用，包括使用从SEQ ID NO：1的序列生产重组蛋白的那些。
-
5.发明授权公开(公告)号：US06995133B1
公开(公告)日：2006-02-07
申请号：US09674445
申请日：1999-05-13
CPC分类号： A61K38/212 , Y10S514/893 , Y10S514/894
摘要： The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFNα5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the subtype alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFNα5. These significant differences between the expression patterns of some livers an others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatopathies. The invention discloses in details such utilization in different forms and processes, including those which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.
摘要翻译： 本发明涉及干扰素α5在病毒性肝病的治疗中的应用。 本发明描述了与健康肝脏相比，丙型肝炎患者肝脏中IFNα5的合成减少。 在所述健康肝脏中表达的IFN的亚型与仅在肝脏中表达的不同亚型相比仅对应于α5亚型。 序列SEQ ID NO：1显示对应于IFNα5的cDNA的部分序列。 一些肝脏的表达模式之间的这些显着差异表明了使用这种干扰素亚型在制备可用于治疗病毒性肝病的组合物中的重要性。 本发明详细公开了不同形式和方法的这种利用，包括使用从SEQ ID NO：1的序列生产重组蛋白的那些。
-
公开(公告)号：US07501392B2
公开(公告)日：2009-03-10
申请号：US11212126
申请日：2005-08-25
CPC分类号： A61K38/212 , Y10S514/893 , Y10S514/894
摘要： The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFNα5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the subtype alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFNα5. These significant differences between the expression patterns of some livers an others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatopathies. The invention discloses in details such utilization in different forms and processes, including those which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.
摘要翻译： 本发明涉及干扰素α5在病毒性肝病的治疗中的应用。 本发明描述了与健康肝脏相比，丙型肝炎患者肝脏中IFNα5的合成减少。 在所述健康肝脏中表达的IFN的亚型与仅在肝脏中表达的不同亚型相比仅对应于α5亚型。 序列SEQ ID NO：1显示对应于IFNα5的cDNA的部分序列。 一些肝脏的表达模式之间的这些显着差异表明了使用这种干扰素亚型在制备可用于治疗病毒性肝病的组合物中的重要性。 本发明详细公开了不同形式和方法的这种利用，包括使用从SEQ ID NO：1的序列生产重组蛋白的那些。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.02 秒)
